Publications

Sort by: Date | Author | Title

von Heymann, A., Finsted, E., Guldin, M. B., Andersen, E. A. W., Dammeyer, J., Sjøgren, P., von der Maase, H., Benthien, K. S., Kjellberg, J., Johansen, C. & Bidstrup, P. (2023). Effects of home-based specialized palliative care and dyadic psychological intervention on caregiver burden: results from a randomized controlled trial. Acta Oncologica, 62(7), 803-807. https://doi.org/10.1080/0284186X.2023.2194491
Hochberg, Z., Albertsson-Wikland, K., Privé, F., German, A., Holmgren, A., Rubin, L. & Shmoish, M. (2023). Energy Trade-off and 4 Extreme Human Body Types. The Journal of Clinical Endocrinology & Metabolism, 108(5), E89-E97. https://doi.org/10.1210/clinem/dgac665
Bølling-Ladegaard, E. (2023). Epilepsy, Depression and Drug-Resistance. [PhD dissertation, Aarhus University].
Ekdahl, D. (2023). Esports and Intercorporeality. Abstract from Nordic Workshop in the Philosophy of Games, Jyväskylä, Finland.
Struijs, F., Hooijmans, C. R., Buijs, M., Dahan, A., Hoffmann, S., Kiffen, R., Mandrioli, D., Menon, J., Ritskes-Hoitinga, M., Roeleveld, N., de Ruijter, A., Scheffer, G. J., Schlünssen, V. & Scheepers, P. T. J. (2023). Establishing a health-based recommended occupational exposure limit for isoflurane using experimental animal data: a systematic review protocol. Systematic Reviews, 12(1), Article 166. https://doi.org/10.1186/s13643-023-02331-0
ESBACE Consortium and ESBACE Collaborators (2023). Estimates of epilepsy prevalence, psychiatric co-morbidity and cost. Seizure, 107, 162-171. https://doi.org/10.1016/j.seizure.2022.06.010
Ghimire, K., McLachlan, C. S., Mishra, S. R., Kallestrup, P. & Neupane, D. (2023). Estimating mean population salt intake using spot urine samples in Nepal: a cross-sectional study. Journal of Hypertension, 41(5), 711-722. https://doi.org/10.1097/HJH.0000000000003380
Cook, R. R., Foot, C., Arah, O. A., Humphreys, K., Rudolph, K. E., Luo, S. X., Tsui, J. I., Levander, X. A. & Korthuis, P. T. (2023). Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. Addiction Science and Clinical Practice, 18(1), Article 11. https://doi.org/10.1186/s13722-023-00364-3